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ABSTRACT
The incidence, risk factors and prognostic factors for candidal infection were determined in a
prospective study of 280 infected patients. Thirty-one (11%) patients were infected with Candida spp.,
sub-divided into 18 (58%) with C. albicans, and 13 (42%) with non-albicans spp. (six C. glabrata, three
C. parapsilosis, and one each of C. krusei, C. tropicalis, C. guilliermondii and C. lusitaniae). Infection with
Candida spp. was always associated with concurrent bacterial infection. By univariate logistic regression
analysis, the degree of morbidity and the duration of mechanical ventilation were independent
predictive factors for death, but infection with Candida spp., was not. Factors associated with Candida
spp. infection were the degree of morbidity, intensive care unit length of stay, alterations of immune
response, and the number of medical devices involved. By multivariate logistic regression analysis, the
only independent risk factor for candidal infection was intensive care unit length of stay.
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INTRODUCTION
The incidence of fungal infections in intensive
care units (ICUs) has increased dramatically in
recent years. The National Nosocomial Infections
Surveillance system in the USA reported an
overall increase in the rate of fungal infections
from 2.0 infections ⁄ 1000 patients discharged in
1980 to 3.8 infections ⁄ 1000 patients discharged in
1990 [1]. Similarly, Voss et al. [2] noted an
increased incidence of candidaemia, from 4.7
cases ⁄ 10 000 patient-days in 1987 to 7.4
cases ⁄ 10 000 patient-days in 1994, at a large
Dutch university hospital. Studies now report
that fungi are involved in up to 17% of all
nosocomial infections [3,4], and 9–12% of nosoco-
mial bloodstream infections [5–7]. This increase in
fungal infections is multifactorial and reﬂects an
increased number of immunocompromised and
elderly patients requiring intensive care,
increased recognition, better diagnostic testing,
greater use of antibiotic drugs, improvements in
life-support systems, and frequent use of invasive
procedures [8].
Candida spp. are the most common cause of
fungal infection in critically ill patients, account-
ing for 85% of fungal isolates in the National
Nosocomial Infections Surveillance System study
[7]. Candida albicans is responsible for 60% of
candidal infections [2,9], but non-albicans species
are emerging increasingly as signiﬁcant ICU
pathogens [10,11]. In one study on candidaemia
in the ICU, non-albicans strains were responsible
for 15% of infections in 1991 and 56% in 1994 [2].
This report describes a prospective study in
critically ill patients to compare the morbidity and
mortality rates in patients infected with Candida
spp. with those in patients with bacterial infec-
tions, with the hypothesis that patients infected
with Candida spp. would have a higher magni-
tude of organ failure and a worse outcome. The
factors that predicted candidal infection and
mortality were also assessed.
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PATIENTS AND METHODS
The study was conducted prospectively in three distinct
periods (April to June 1999, October to November 1999, June
to September 2000) in a 31-bed medical-surgical intensive care
department of a tertiary care hospital. Patients who stayed in
the ICU for < 24 h were excluded. Data recorded included age,
gender, cause of ICU admission (medical or surgical), previous
hospital stay, total length of ICU stay, length of ICU stay after
diagnosis of infection, use and duration of mechanical
ventilation, haemodialysis or haemoﬁltration, previous anti-
biotic use, previous immunosuppressive therapy, APACHE
(Acute Physiologic and Chronic Health Evaluation) II score
[12], SOFA (Sequential Organ Failure Assessment) score [13] at
admission (SOFA0), maximum SOFA score during ICU stay
(SOFAm), SOFA score on the day of diagnosis of infection
(SOFAinf), daily blood C-reactive protein concentrations, num-
ber of medical devices (including endotracheal tube, arterial
line, peripheral and central venous catheters, pulmonary
artery catheter, Foley catheter, surgical drains), administration
of parenteral nutrition, antifungal treatment and outcome.
Procalcitonin levels were measured in 157 patients as part of
the routine monitoring in these patients at the time of the
study.
Patients were divided retrospectively into two groups
according to the absence (group A) or presence (group B) of
candidal infection. Candidaemia was deﬁned as: (1) one blood
culture that grew Candida spp. and either histologically
documented invasive candidiasis or ophthalmic examination
consistent with candidal endophthalmitis; (2) at least two
blood cultures obtained at different times from a peripheral
vein that grew the same Candida sp.; or (3) one blood culture
obtained peripherally and one blood culture obtained through
an indwelling central line, both of which grew an identical
Candida sp. [4]. Patients with one positive blood culture drawn
through an intravenous line and a positive semi-quantitative
catheter tip culture were not considered infected unless they
satisﬁed one of the other criteria. Severe non-bloodstream
candidal infections were deﬁned as Candida spp. isolated from
a normally sterile body site, and the presence of at least one of
the following: fever (‡ 38.5 C), or hypothermia (< 36 C);
unexplained prolonged arterial hypotension (systolic blood
pressure of < 90 mmHg for at least 2 h, unresponsive to
volume challenge); or absence of response to adequate
antibiotic treatment for a suspected bacterial infection [4].
Infections were deﬁned according to the Centers for Disease
Control guidelines [14].
Yeast isolates were identiﬁed by the API ID 32C system
(bioMe´rieux, Marcy-l’Etoile, France) and growth on CHROM-
agarCandidamedium(CHROMagar, Paris, France).Antifungal
susceptibility testing for ﬂuconazole, itraconazole, 5-ﬂucyto-
sine, ketoconazole and amphotericin B was performed by
Sensititre YeastOne (Trek Diagnostic Systems, Westlake, OH,
USA) according to the manufacturer’s recommendations. Sus-
ceptibility breakpoints for ﬂuconazole, itraconazole and
5-ﬂucytosine were those recommended by the National Com-
mittee for Clinical Laboratory Standards [15]. For amphotericin,
a susceptibility breakpoint has not yet been deﬁned, but for this
study, susceptibility was deﬁned as an MIC of £ 1 mg ⁄L, based
on the literature [16]. MICs were expressed as susceptible,
susceptible but dose-dependent, or resistant, according to the
National Committee for Clinical Laboratory Standards recom-
mendations [15].
Statistical analysis
Student’s t-test was used to compare continuous variables and
a chi-square test to compare categorical data. Results are
expressed as mean values ± SD. Univariate and multivariate
logistic regression analyses (STATISTIX 3.1 software; Analyt-
ical Software, Tallahassee, FL, USA) were performed to
identify variables associated with high-risk factors. For all
statistical analyses, p < 0.05 was considered to be statistically
signiﬁcant.
RESULTS
Of 949 patients who stayed in the ICU for > 24 h,
280 (29%) had, or developed, an infection. Of
those, 249 (89%) had a bacterial infection (group B)
and 31 (11%) met the criteria for candidal infection
(group A). Hence, the proportion of ICU patients
with candidal infection was 3%. The mean time of
onset of candidal infection was 9 ± 3 days after
ICU admission. The characteristics of the infected
patients are presented in Table 1. C. albicans was
identiﬁed in 18 (58%) patients, and non-albicans
species in 13 (42%; Fig. 1).
The main site of infection was the bloodstream,
including catheter-related infections, followed by
lung, abdomen and urinary tract (Table 2). There
were no signiﬁcant differences regarding the site
of infection between C. albicans and non-albicans
species.
Infection with Candida spp. in all cases fol-
lowed a bacterial infection (mean 5 ± 2 days
after the onset of bacterial infection). Bacterial
pathogens included resistant organisms (58%),
notably methicillin-resistant Staphylococcus aureus
(11 patients), Enterobacter aerogenes (three
patients), Klebsiella pneumoniae (two patients)
and Acinetobacter baumannii (two patients), and
susceptible strains (42%), notably Pseudomonas
aeruginosa (seven patients), E. aerogenes (three
patients), methicillin-sensitive S. aureus (ﬁve
patients), K. pneumoniae (two patients) and
Enterococcus faecalis (four patients).
There was no difference between the two
groups in age, gender or type of patient (med-
ical ⁄ surgical). There was also no difference
between the two groups in the degree of morbid-
ity, as assessed by both the APACHE II and SOFA
scores, except that the degree of organ failure on
the day the infection was diagnosed (SOFAinf)
was higher in the patients with candidal infection
(9.8 ± 1.3 vs. 7.0 ± 3.0; p 0.03). Patients with
candidal infection had a longer total length of
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stay (p 0.02), a longer length of stay after diagno-
sis of infection (p 0.03), and a greater application
and duration of mechanical ventilation (p 0.04
and p 0.03, respectively) and of haemodialysis
(p 0.03) than patients with bacterial infection.
Mortality was also higher in patients infected
with Candida spp., although this difference was
not statistically signiﬁcant (48% vs. 37%; p 0.09).
Mortality was similar in patients infected with
albicans and non-albicans species (47% vs. 50%).
By univariate logistic regression, the degree of
morbidity and the duration of mechanical venti-
lation, were independent predictive factors for
death, but infection with Candida spp. was not.
There were no differences regarding the degree
of immunosuppression or the administration of
Table 1. Characteristics of infected
patients
Infection with Candida
spp. (group A)
n = 31
Bacterial infection
alone (group B)
n = 249 p value
Age (range) in years 64 (24–81) 58 (18–81) NS
Medical:surgical patients 16:15 162:87 NS
APACHE II 18.4 ± 6.0 17.0 ± 7.0 NS
SOFA0 8.4 ± 1.6 7.0 ± 3.0 NS
SOFAm 10.4 ± 1.3 9.0 ± 4.0 NS
SOFAinf 9.8 ± 1.3 7.0 ± 3.0 0.03
Hospital stay before ICU
admission (days)
4.6 ± 5.6 3.0 ± 3.3 NS
Total length of ICU stay (days) 18 (12–36)b 9 (2–68) 0.02
Length of ICU stay after
diagnosis of infection (days)
10 (8–22)b 5 (3–11) 0.03
Duration of mechanical
ventilation (days)
10.9 ± 4.1b 4.0 ± 4.7 0.03
Duration of haemodialysis (days) 1.7 ± 2.2b 0.6 ± 2.3 0.03
Immunosuppression 10 ⁄ 31 (32%) 74 ⁄ 249 (30%) NS
Parenteral nutrition 9 ⁄ 31 (29%) 66 ⁄ 249 (26%) NS
AB therapy
Number ⁄day 3.6 ± 1.4b 1.6 ± 2.0 0.02
Total number of days 14.4 ± 4.4b 5.2 ± 6.1 0.01
Previous AB daysa 11 ± 3 –
Previous AB number ⁄daya 2.1 ± 3.2 –
Number of medical devices 2.6 ± 1.5 2.6 ± 1.5 NS
Blood levels of CRP 16.3 ± 6.0 13.4 ± 8.8 NS
Blood levels of PCT 4.4 ± 4.6 4.1 ± 3.7 NS
Mortality 15 (48%) 92 (37%) 0.09
ICU, intensive care unit; AB, antibiotic; CRP, C-reactive protein; PCT, procalcitonin; APACHE II, Acute Physiologic
and Chronic Health Evaluation II score; SOFA, Sequential Organ Failure Assessment score; NS, not signiﬁcant.
aBefore Candida spp. infection.
bGroup A vs. group B.
Candida albicans
59%
Candida parapsilosis
10%
Candida krusei
3%
Candida tropicalis
3% Candida lusitaniae
3%
Candida guilliermondii
3%
Candida glabrata
19%
Fig. 1. Distribution of Candida spp.
isolated from the 31 infected
patients.
Table 2. Source of infections in
patients with Candida spp.Source of
infection
Candida spp.
infections
n = 31
Candida
albicans
n = 18
Candida
non-albicans
n = 13
Positive blood
culture
Candida
endophthalmitis
Blooda 14 8 6 14 8
Lung 8 4 4 8 4
Abdomen 6 4 2 6 4
Urine 3 2 1 3 2
aIncluding catheter-related infections.
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parenteral nutrition between the two groups of
patients. There were no signiﬁcant differences in
blood levels of C-reactive protein or procalcitonin
between the two groups on the day that infection
was diagnosed.
Patients with Candida spp. infection received
more antibiotics, with a signiﬁcant difference in
the total use of antibiotics in days (14.4 ± 4.4 vs.
5.2 ± 6.1 days; p 0.01) and in the number of
antibiotics ⁄day (3.6 ± 1.4 vs. 1.6 ± 2.0; p 0.02).
Univariate logistic regression revealed the
degree of morbidity (p 0.01), the length of ICU stay
(p 0.03), previous antibiotic use (p 0.03), the use of
mechanical ventilation (p 0.03) and the number of
medical devices (p 0.04) as independent factors
associatedwithCandida spp. infection compared to
bacterial infection. Multivariate logistic regression
revealed only the ICU length of stay as an inde-
pendent predictor for candidal infection (p 0.03).
Among the 31 infected patients, 20 were treated
effectively with ﬂuconazole, and eight with
amphotericin B; three patients who were
unresponsive to ﬂuconazole were switched to
amphotericin B. The MICs for the antifungal
agents tested are presented in Fig. 2.
DISCUSSION
The incidence of Candida spp. infections is
increasing [1], along with a shift towards non-
albicans spp. [10]. In the present study, an infec-
tion with Candida spp. was diagnosed in 3% of
patients admitted for > 24 h to the ICU, repre-
senting 11% of all infections. This result is in
agreement with data from the EPIC study [3],
showing that 17.1% of infected patients had a
fungal infection. Importantly, the incidence of
Candida spp. infections is highly dependent on the
patient population. The ICU department investi-
gated in the study was mixed medical-surgical,
but did not include haematology patients;
therefore, the results cannot be generalised to
ICUs that include neutropenic patients.
Non-albicans species were found in 42% of
patients infected with Candida spp. In a retrospec-
tive study, Blot et al. [17] found that, of 57 cases of
candidaemia, 41 (72%) were caused by C. albicans
and 16 (28%) by non-albicans species, while Nucci
et al. [18] reported 37% C. albicans and 63%
non-albicans in a series of 145 patients with can-
didaemia. According to the National Nosocomial
Fig. 2. Distribution of the MICs
(interquartile with 10–90% range)
of antifungal agents for the C. albi-
cans and non-albicans isolates from
the 31 patients infected with Candida
spp.
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Infections Surveillance System [19], C. albicanswas
responsible for 76%, and non-albicans species for
10%, of nosocomial fungal infections between 1980
and 1990. The differences between the percentages
ofCandida spp. found in the different studies can be
attributed largely to variations in local microﬂora.
Infections involving Candida spp. have high
fatality rates in modern critical care settings.
Because of great variabilities in demographic
characteristics, severity of disease and deﬁnitions
of Candida spp. infections, outcome comparisons
are difﬁcult to perform. The crude mortality rate
in this study was 48% for patients with Candida
spp., compared to 37% in patients with bacterial
infection. In a well-matched case control study of
candidaemia in ICU patients, Wey et al. [20]
reported a crude mortality rate of 57%, while
Petri et al. [21] observed a mortality rate of 31% in
a series of 251 patients with at least one positive
Candida spp. culture.
Serial blood levels of C-reactive protein and
procalcitonin have been proposed as markers of
fungal infections [22,23]. In the present study,
there was no difference between the levels of
these markers in patients infected with Candida
spp. and in those who had a bacterial infection,
but since all Candida spp. infections were associ-
ated with a bacterial infection, any direct associ-
ation with fungal infection is difﬁcult to assess.
Many risk factors for infections with Candida
spp. have been identiﬁed, including Candida
colonisation [24], candiduria [25], use of antibiot-
ics [20,26], severity of underlying disease [4,26],
alterations of immune response [27,28], central
venous catheters [29], total parenteral nutrition
[29], major surgical operations [29], states of
altered tissue perfusion [30], malnutrition [30],
diabetes [30], trauma [30], cancer [30], chemother-
apy [30] and acute renal failure [29]. In our series,
univariate logistic regression revealed the degree
of morbidity, the total length of ICU stay, previ-
ous antibiotic use, the use of mechanical ventila-
tion and the number of medical devices as
independent factors associated with Candida spp.
infection compared to bacterial infection, but a
multiple logistic model found that only the ICU
length of stay was an independent predictor for
Candida spp. infection. Interestingly, although
described increasingly in ICU patients [31–34],
antifungal resistance was not a problem in the
patients studied. This ﬁnding may be explained
by the small number of patients included, or
perhaps also by the strict policy for antifungal
administration in our department.
It was concluded that infections with Candida
spp. in critically ill patients were associated with
the presence of other infections, and particularly
with resistant bacterial strains. A longer length of
ICU stay is predictive of infection with Candida
spp.
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